AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic Area

Inclusion Criteria: * Healthy infants aged 10 weeks and 5-12 months at the time of enrollment with consenting parents. Exclusion Criteria: * Clinically significant history of skin disorder (psoriasis, contact dermatitis etc.), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness. * Severe malnutrition. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g. egg products, Kathon, neomycin, betapropiolactone. * History of splenectomy Haemoglobin less than 8.0 g/dL, where judged to be clinically significant in the opinion of the investigator * Serum Creatinine concentration greater than 70 mol/L, where judged to be clinically significant in the opinion of the investigator * Serum ALT concentration greater than 45 U/L, where judged to be clinically significant in the opinion of the investigator * Blood transfusion within one month of enrollment. * History of vaccination with previous experimental malaria vaccines. -Administration of any other vaccine or immunoglobulin less than two weeks before vaccination with the IMPs Current participation in another clinical trial, or within 12 weeks of this study. * Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial. * Likelihood of travel away from the study area * Maternal HIV infection Positive malaria antigen test at screening * Failure to have received, prior to enrollment, the routine EPI vaccinations due according to the Gambian EPI schedule.